Form 4: Xeris Biopharma COO Kevin McCulloch Boosts Stake with Significant Share Purchase

Xeris Biopharma Holdings, Inc.'s President and Chief Operating Officer, Kevin McCulloch, has acquired 25,000 shares of common stock, signaling increased insider confidence in the company.

Summary

• Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma Holdings, Inc., purchased 25,000 shares of common stock.
• The transaction occurred on June 13, 2025.
• The shares were acquired at a weighted average price of $4.379 per share, with prices ranging from $4.3750 to $4.380.
• Following this transaction, Kevin McCulloch directly beneficially owns 1,708,585 shares of common stock.
• Additionally, 25,000 shares are indirectly owned by his spouse and 2,000 shares by the Charles R. McCulloch Trust dated 1990, though the reporting person disclaims beneficial ownership except for pecuniary interest.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 8

Explanation: The purchase of a significant number of shares by a high-ranking executive like the COO is a strong positive signal, indicating confidence in the company's future. The transaction being under a 10b5-1 plan also suggests a pre-meditated belief in the company's value.

Positives

• A significant purchase of 25,000 shares by a key executive, the President and COO, indicates strong insider confidence in the company's future prospects.
• The transaction was executed at a price of $4.379 per share, suggesting management believes the stock is undervalued or poised for growth at this price point.
• The purchase was made under a Rule 10b5-1(c) plan, which suggests a pre-planned investment strategy rather than a reaction to immediate market events.

Future Outlook

NA

Management Comments

• Kevin McCulloch, President and Chief Operating Officer, acquired 25,000 shares of common stock, demonstrating a direct investment in the company's equity.

Industry Context

Insider purchases, especially by high-ranking executives like a COO, are often viewed positively by the market as they signal management's belief in the company's future performance and value, which can be particularly impactful in the biopharma sector where R&D outcomes and regulatory approvals carry significant weight.

Related Party Transactions

• Kevin McCulloch disclaims beneficial ownership of 25,000 shares held indirectly by his spouse and 2,000 shares held indirectly by the Charles R. McCulloch Trust dated 1990, except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator of management's belief in the company's future, potentially increasing investor confidence and demand for the stock.

Key Dates

Recommendation

Keywords

Xeris Biopharma Holdings Inc., XERS, Kevin McCulloch, Insider Trading, Form 4, Share Purchase, Common Stock, Biopharma, Executive Stock Purchase, Rule 10b5-1